Searchable abstracts of presentations at key conferences in endocrinology

ea0012p121 | Steroids to include Cushing's | SFE2006

Role of glucocorticoids and AMPK in the regulation of lipogenesis and glycerogenesis in mesenteric adipose tissue

Lolli F , Christ-Crain M , Kola B , Wittman G , Fekete C , Grossman AB , Korbonits M

CushingÂ’s syndrome is characterized by a diverse set of clinical manifestations, including hypertension, apparent obesity and metabolic aberrations such as diabetes, dyslipidaemia, ultimately leading to the metabolic syndrome. AMP-activated protein kinase (AMPK) is an intracellular energy sensor. It integrates nutritional and hormonal signals by switching on catabolic pathways, such as fatty acid oxidation and glycolysis and switching off anabolic pathways, such as fatty ...

ea0011oc25 | Diabetes and metabolism | ECE2006

Cannabinoids increase AMP-activated protein kinase (AMPK) enzyme activity in the hypothalamus and heart via different signalling pathways – studies in CB1 knockout animals

Kola B , Christ-Crain M , Wittman G , Leontiou C , Grossman A , Fekete C , Korbonits M

We have recently reported that cannabinoids can stimulate hypothalamic and heart AMPK activity and can inhibit liver and adipose tissue AMPK activity in rats (Kola et al., JBC, 2005). These data are in accordance with the known orexigenic and adipogenic cannabinoid effects and also with their beneficial effects on the ischaemic heart. We have studied the effects of cannabinoids on AMPK activity in tissues from wild type (WT) and CB1 knockout (KO) mice to see if the CB1 ...